{"id":"W2782361381","doi":"10.1186/s13075-017-1496-5","title":"One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry","year":2018,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"UCB Pharma; Genentech; Horizon Pharma; Momenta Pharmaceuticals; Valeant Pharmaceuticals International; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Certolizumab pegol; Medicine; Golimumab; Etanercept; Adalimumab; Rheumatoid arthritis; Infliximab; Internal medicine; Abatacept; Incidence (geometry); Propensity score matching; Cohort; Rheumatology; TNF inhibitor; Adverse effect; Disease; Rituximab; Lymphoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":{"n_in":0,"stratum":"fund_new","weight":1678.9,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"medium","reason":"Registry comparison of infection risk across TNF inhibitors that applies propensity matching to reduce channeling bias; bias adjustment is used as a tool and the knowledge produced is about drug safety."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"The registry study estimates medication safety in rheumatoid arthritis patients rather than studying research practice."},"grok":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Real-world drug safety comparison in RA; uses propensity methods to answer a clinical question, not to study methods."}}}